Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

The “ins and outs” of complement-driven immune responses

(2016) Simon Freeley et al.   IMMUNOLOGICAL REVIEWS

T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells

(2016) G. Arbore et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression

(2016) Y. Wang et al.   Cancer Discovery

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis

(2015) Jianjun Liu et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function

(2015) Eunyoung Chun et al.   Cell Reports

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients

(2014) X Wu et al.   BRITISH JOURNAL OF CANCER

Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche

(2014) S. K. Vadrevu et al.   CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Autocrine Effects of Tumor-Derived Complement

(2014) Min Soon Cho et al.   Cell Reports

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells

(2014) Sarah K Maenhout et al.   OncoImmunology

Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer

(2013) Jie Gu et al.   LUNG CANCER

C5aR Expression in a Novel GFP Reporter Gene Knockin Mouse: Implications for the Mechanism of Action of C5aR Signaling in T Cell Immunity

(2012) J. Dunkelberger et al.   JOURNAL OF IMMUNOLOGY

Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression

(2012) Leticia Corrales et al.   JOURNAL OF IMMUNOLOGY

Unwelcome Complement

(2009) M. M. Markiewski et al.   CANCER RESEARCH

Modulation of the antitumor immune response by complement

(2008) Maciej M Markiewski et al.   NATURE IMMUNOLOGY